(Q53644144)

16 May 2018

title

Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). (English)

1 reference

16 May 2018

10

Maciej Kwiatkowski

1 reference

16 May 2018

Franz Recker

9

object named as

Franz Recker

1 reference

16 May 2018

author name string

Marco Randazzo

1

1 reference

16 May 2018

Josef Beatrice

2

1 reference

16 May 2018

Andreas Huber

3

1 reference

16 May 2018

Rainer Grobholz

4

1 reference

16 May 2018

Lukas Manka

5

1 reference

16 May 2018

Felix K Chun

6

1 reference

16 May 2018

Luis A Kluth

7

1 reference

16 May 2018

Stephen F Wyler

8

1 reference

16 May 2018

language of work or name

English

0 references

publication date

23 January 2015

1 reference

16 May 2018

International Journal of Cancer

published in

1 reference

16 May 2018

volume

137

1 reference

16 May 2018

page(s)

553-559

1 reference

16 May 2018

issue

3

1 reference

16 May 2018

International variation in prostate cancer incidence and mortality rates.

cites work

1 reference

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

21 January 2018

1 reference

Overdiagnosis and overtreatment of prostate cancer

21 January 2018

1 reference

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

21 January 2018

1 reference

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

21 January 2018

1 reference

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

21 January 2018

1 reference

Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review

21 January 2018

1 reference

Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.

21 January 2018

1 reference

Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).

21 January 2018

1 reference

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

21 January 2018

1 reference

Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland.

21 January 2018

1 reference

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

A comparison of US and Australian men's values and preferences for PSA screening

21 January 2018

1 reference

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

21 January 2018

1 reference

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

Early detection of prostate cancer: European Association of Urology recommendation

21 January 2018

1 reference

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

21 January 2018

1 reference

Quality-of-life effects of prostate-specific antigen screening.

21 January 2018

1 reference

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29420

1 reference

16 May 2018

PubMed ID

25565393

1 reference

16 May 2018